BR112015021846A2 - biomarcador - Google Patents

biomarcador

Info

Publication number
BR112015021846A2
BR112015021846A2 BR112015021846A BR112015021846A BR112015021846A2 BR 112015021846 A2 BR112015021846 A2 BR 112015021846A2 BR 112015021846 A BR112015021846 A BR 112015021846A BR 112015021846 A BR112015021846 A BR 112015021846A BR 112015021846 A2 BR112015021846 A2 BR 112015021846A2
Authority
BR
Brazil
Prior art keywords
biomarker
mutation
assay
absence
nucleic acid
Prior art date
Application number
BR112015021846A
Other languages
English (en)
Inventor
Wilson Christopher
Chen Jinyun
Zhou Wenlai
Chen Yaoyu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112015021846A2 publication Critical patent/BR112015021846A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cell Biology (AREA)

Abstract

resumo patente de invenção: "biomarcador". a presente invenção refere-se, em parte, a regimes de tratamento seletivo de câncer baseados no ensaio para a presença ou ausência de uma mutação em um ácido nucleico que codifica mll1 ou para a presença de reduzidos níveis de mll1.
BR112015021846A 2013-03-15 2014-03-14 biomarcador BR112015021846A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361802327P 2013-03-15 2013-03-15
PCT/IB2014/059826 WO2014141194A2 (en) 2013-03-15 2014-03-14 Biomarker

Publications (1)

Publication Number Publication Date
BR112015021846A2 true BR112015021846A2 (pt) 2017-07-18

Family

ID=50391246

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015021846A BR112015021846A2 (pt) 2013-03-15 2014-03-14 biomarcador

Country Status (11)

Country Link
US (1) US20160031836A1 (pt)
EP (1) EP2968349A2 (pt)
JP (1) JP2016512812A (pt)
KR (1) KR20150131155A (pt)
CN (1) CN105050603A (pt)
AU (2) AU2014229240B2 (pt)
BR (1) BR112015021846A2 (pt)
CA (1) CA2902699A1 (pt)
MX (1) MX2015013197A (pt)
RU (1) RU2015144019A (pt)
WO (1) WO2014141194A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160371957A1 (en) * 2015-06-22 2016-12-22 Mc10, Inc. Method and system for structural health monitoring
RU2689400C1 (ru) * 2018-04-17 2019-05-28 Федеральное Государственное Бюджетное Учреждение Науки Институт Молекулярной Биологии Им. В.А. Энгельгардта Российской Академии Наук (Имб Ран) Способ анализа полиморфных маркеров в генах VKORC1, CYP4F2, CYP2C9, CYP2C19, ABCB1, ITGB3 для определения индивидуальной чувствительности к противосвертывающим препаратам
CN108570501B (zh) * 2018-04-28 2020-06-12 北京师范大学 多发性骨髓瘤分子分型及应用
WO2020206608A1 (en) 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co., Ltd. Methods and compositions for targeted protein degradation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1611112T3 (da) * 2003-02-11 2012-11-19 Cancer Res Inst Isoxazolforbindelser som hæmmere af varmechokproteiner
TW200922595A (en) * 2007-10-12 2009-06-01 Novartis Ag Organic compounds
US20110319415A1 (en) * 2008-08-18 2011-12-29 Universit+e,uml a+ee t zu K+e,uml o+ee ln Susceptibility to HSP90-Inhibitors
CN101445832B (zh) * 2008-12-23 2011-09-14 广州益善生物技术有限公司 Pik3ca基因突变的检测探针、液相芯片及其检测方法
PL2488873T3 (pl) * 2009-10-16 2016-01-29 Novartis Ag Biomarkery odpowiedzi farmakodynamicznej wobec guza
CA2779843A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
EA028984B1 (ru) * 2012-03-29 2018-01-31 Новартис Аг Применение (s)-пирролидин-1,2-дикарбоновой кислоты 2-амид 1-({4-метил-5-[2-(2,2,2-трифтор-1,1-диметилэтил)пиридин-4-ил]тиазол-2-ил}амида) для лечения рака

Also Published As

Publication number Publication date
WO2014141194A2 (en) 2014-09-18
EP2968349A2 (en) 2016-01-20
JP2016512812A (ja) 2016-05-09
AU2014229240B2 (en) 2017-06-15
MX2015013197A (es) 2016-07-07
AU2017203395A1 (en) 2017-06-08
WO2014141194A3 (en) 2015-01-08
KR20150131155A (ko) 2015-11-24
CN105050603A (zh) 2015-11-11
AU2014229240A1 (en) 2015-09-17
RU2015144019A (ru) 2017-04-24
RU2015144019A3 (pt) 2018-04-03
US20160031836A1 (en) 2016-02-04
CA2902699A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
BR112017020893A2 (pt) método para o tratamento de câncer
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112017006664A2 (pt) terapias de combinação
BR112015007184A2 (pt) combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer
EA201590554A1 (ru) Ингибиторы глюкозилцерамид-синтазы
EA201690881A1 (ru) Соединения-ингибиторы аутотаксина
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
BR112019007613A2 (pt) terapia de combinação para inibição de c3
AR090903A1 (es) Anticuerpos e inmunoconjugados anti-pmel17
ECSP14013152A (es) Compuestos inhibidores de metaloenzimas
BR112015022047A2 (pt) métodos para tratar câncer de bexiga
BR112014002817A2 (pt) Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62
BR112017021312A2 (pt) tratamento de câncer de pulmão com inibidores de glutaminase
PH12015501071A1 (en) Combination therapy of anti-her3 antibodies
CY1121859T1 (el) Μεθοδος παρασκευης αναστολεων συνθασης γλυκοζυλοκεραμιδης
BR112014024269A8 (pt) Anticorpo ou um fragmento de ligação a antígeno do anticorpo, fragmento de ligação a antígeno do anticorpo, composição farmacêutica, uso de um anticorpo ou um fragmento de ligação a antígeno, uso de uma composição, vetor, célula hospedeira transformada, e, método para produzir um anticorpo
BR112015002739A2 (pt) métodos para intensificar, melhorar ou sustentar saúde e/ou função cognitiva em mamíferos, e para tratar ou prevenir um declínio em saúde e/ou função cognitiva em mamíferos
BR112017013576A2 (pt) produção melhorada de lipídios de núcleo em leveduras oleaginosas
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
BR112018006810A2 (pt) regimes de dosagem
BR112015021846A2 (pt) biomarcador
EA201490767A1 (ru) Кластер генов биосинтеза гризелимицина и метилгризелимицина
TR201910413T4 (tr) Benralizumab kullanarak astım semptomlarının iyileştirilmesine yönelik yöntemler.
NZ712023A (en) Caix stratification based cancer treatment
BR112017024163A2 (pt) compostos bicíclicos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements